EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

DIURETICS INTERACTIONS WITH MEDICATIONS USED IN THE MANAGEMENT OF CONGESTIVE HEART FAILURE AND OTHER CO-MORBID CONDITIONS: AN INDICATION FOR CONSTANT DRUG THERAPY MONITORING AND VIGILANCE

*John David Ohieku and Muhammad Al-Amin Usman

ABSTRACT

Background: Many patients are worried receiving medications that have adverse drug interactions that will further affect their health status. Objectives: The objectives were to assess potential interactions between three classes of diuretic with other medications and to evaluate the potential clinical outcomes as well as to identify patients that may require constant monitoring and vigilance. Methods: The cross-sectional and prospective study involve the evaluation of drug interaction between diuretics and other medications using online drug interaction software checkers developed by Medscape.com, Drug.com, Drugbank.com and Epocrates online. Results: The proportion of patients recommended for diuretics among the middle aged adult was 41.7%, 34.3% and 20.0% for loop, K-sparing and thiazide diuretics respectively. Drugs co-used with loop diuretic when compared with the total number of such drugs in the entire study were as high as 75% each for atorvastatin, nifedipine, captopril and carvedilol; and as low in thiazide combinations with amiodarone (4.8%), CaCO3(6.4% ), calcitriol (7.5%) and allopurinol (13.6%). Out of 23 paired interactions that occurred between loop diuretic and other medications, 21(91.3%) were single interaction while 2(8.7%) were double interactions. With K-sparing diuretic interactions and other medications 18(90.0%) were single while 1(5.0%) each were double and quartet interactions respectively. In thiazide diuretics single interaction were 19(90.5%) while double and triple interactions were 1(4.76%) each. Pharmacokinetic versus pharmacodynamics interactions were 49(10.7%) versus 407(89.3%); 56(17.7%) versus 260(82.3%); and 8(12.5%) versus 56(87.5%) in loop, K-sparing and thiazide diuretics respectively with an overall Pharmacokinetic and pharmacodynamics interactions of 113(13.5%) versus 723(86.5%) respectively. A total of 19 potential outcomes resulting from 124 drug pairs, which accumulated to 1944 outcome cases were observed. Antagonism to potassium levels were the highest being 546 (28.1%). Others are increased risk of hyperkalemia 228(11.7%), risk of hypokalemia 16(0.8%), risk of hypotension 486(25.0%), risk of QT prolongation 2(0.1%), agents whose effects/levels is decreased by diuretic 120(6.2%), risk of SIADH 2(0.1), increase risk of adverse effects 88(4.5%) while risk of nephrotoxicity 26(1.3%), risk of decrease in the therapeutic effects/efficacy of diuretic 35(1.8%) and agents whose effects/therapeutic efficacy may be increased 190 (9.8%) may be potentially present. Combinations requiring monitoring K-levels accounted for 790 (41.3%). BP monitoring may be required in 486(25.4%) cases while downward and upward dosage adjustment of interacting drugs may be necessary in 289(15.1%) and 185(9.7%) cases respectively. Similarly diuretic upward and downward dosage modifications may be required in 36(1.9%) and 17(0.9%) cases respectively. Conclusion: Several potential drug interactions may be present in CHF Patients on diuretics with co-morbid diseases requiring medications. This calls for the need to keenly monitor all medications used by CHF patients as potentially lethal interactions may be present.

Keywords: Diuretic interactions, potassium sparing diuretic, loop diuretic, thiazide diuretic, Furosemide, Spironolactone, Congestive Heart Failure.


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 December 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: DECEMBER ISSUE PUBLISHED

    DECEMBER 2024 issue has been successfully launched on DECEMBER 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along witcertificate to promote resear activity of scholar.

Best Article of current issue :

Dr. Kartik Neog
Download Article : Click here